vs
Doximity, Inc.（DOCS）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是Doximity, Inc.的1.1倍（$207.3M vs $185.1M），Doximity, Inc.净利率更高（33.3% vs -62.0%，领先95.3%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 9.8%），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 25.2%）
Doximity Inc成立于2010年，是面向医疗专业人士的线上社交服务平台，为平台会员提供精选医疗资讯、远程医疗工具，以及病例协作相关功能，助力医疗从业者高效交流信息、开展诊疗相关工作。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
DOCS vs RARE — 直观对比
营收规模更大
RARE
是对方的1.1倍
$185.1M
营收增速更快
RARE
高出16.1%
9.8%
净利率更高
DOCS
高出95.3%
-62.0%
两年增速更快
RARE
近两年复合增速
25.2%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $185.1M | $207.3M |
| 净利润 | $61.6M | $-128.6M |
| 毛利率 | 89.9% | — |
| 营业利润率 | 38.9% | -54.7% |
| 净利率 | 33.3% | -62.0% |
| 营收同比 | 9.8% | 25.9% |
| 净利润同比 | -18.1% | 3.5% |
| 每股收益（稀释后） | $0.31 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DOCSRARE
| Q4 25 | $185.1M | $207.3M | ||
| Q3 25 | $168.5M | $159.9M | ||
| Q2 25 | $145.9M | $166.5M | ||
| Q1 25 | $138.3M | $139.3M | ||
| Q4 24 | $168.6M | $164.6M | ||
| Q3 24 | $136.8M | $139.5M | ||
| Q2 24 | $126.7M | $147.0M | ||
| Q1 24 | $118.1M | $108.8M |
净利润DOCSRARE
| Q4 25 | $61.6M | $-128.6M | ||
| Q3 25 | $62.1M | $-180.4M | ||
| Q2 25 | $53.3M | $-115.0M | ||
| Q1 25 | $62.5M | $-151.1M | ||
| Q4 24 | $75.2M | $-133.2M | ||
| Q3 24 | $44.2M | $-133.5M | ||
| Q2 24 | $41.4M | $-131.6M | ||
| Q1 24 | $40.6M | $-170.7M |
毛利率DOCSRARE
| Q4 25 | 89.9% | — | ||
| Q3 25 | 90.3% | — | ||
| Q2 25 | 89.2% | — | ||
| Q1 25 | 89.5% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 90.0% | — | ||
| Q2 24 | 89.3% | — | ||
| Q1 24 | 89.4% | — |
营业利润率DOCSRARE
| Q4 25 | 38.9% | -54.7% | ||
| Q3 25 | 37.8% | -106.9% | ||
| Q2 25 | 37.4% | -64.8% | ||
| Q1 25 | 35.2% | -102.6% | ||
| Q4 24 | 47.4% | -74.3% | ||
| Q3 24 | 38.8% | -94.6% | ||
| Q2 24 | 36.4% | -79.1% | ||
| Q1 24 | 35.5% | -151.9% |
净利率DOCSRARE
| Q4 25 | 33.3% | -62.0% | ||
| Q3 25 | 36.8% | -112.8% | ||
| Q2 25 | 36.5% | -69.0% | ||
| Q1 25 | 45.2% | -108.5% | ||
| Q4 24 | 44.6% | -80.9% | ||
| Q3 24 | 32.3% | -95.7% | ||
| Q2 24 | 32.7% | -89.5% | ||
| Q1 24 | 34.4% | -156.8% |
每股收益（稀释后）DOCSRARE
| Q4 25 | $0.31 | $-1.28 | ||
| Q3 25 | $0.31 | $-1.81 | ||
| Q2 25 | $0.27 | $-1.17 | ||
| Q1 25 | $0.31 | $-1.57 | ||
| Q4 24 | $0.37 | $-1.34 | ||
| Q3 24 | $0.22 | $-1.40 | ||
| Q2 24 | $0.21 | $-1.52 | ||
| Q1 24 | $0.20 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $64.8M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $979.3M | $-80.0M |
| 总资产 | $1.2B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DOCSRARE
| Q4 25 | $64.8M | $421.0M | ||
| Q3 25 | $169.2M | $202.5M | ||
| Q2 25 | $137.3M | $176.3M | ||
| Q1 25 | $209.6M | $127.1M | ||
| Q4 24 | $165.3M | $174.0M | ||
| Q3 24 | $184.2M | $150.6M | ||
| Q2 24 | $111.4M | $480.7M | ||
| Q1 24 | $96.8M | $112.3M |
股东权益DOCSRARE
| Q4 25 | $979.3M | $-80.0M | ||
| Q3 25 | $1.1B | $9.2M | ||
| Q2 25 | $1.0B | $151.3M | ||
| Q1 25 | $1.1B | $144.2M | ||
| Q4 24 | $1.0B | $255.0M | ||
| Q3 24 | $961.2M | $346.8M | ||
| Q2 24 | $913.6M | $432.4M | ||
| Q1 24 | $901.4M | $140.3M |
总资产DOCSRARE
| Q4 25 | $1.2B | $1.5B | ||
| Q3 25 | $1.3B | $1.2B | ||
| Q2 25 | $1.2B | $1.3B | ||
| Q1 25 | $1.3B | $1.3B | ||
| Q4 24 | $1.2B | $1.5B | ||
| Q3 24 | $1.1B | $1.5B | ||
| Q2 24 | $1.1B | $1.6B | ||
| Q1 24 | $1.1B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.9M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | 0.99× | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
经营现金流DOCSRARE
| Q4 25 | $60.9M | $-99.8M | ||
| Q3 25 | $93.9M | $-91.4M | ||
| Q2 25 | $62.1M | $-108.3M | ||
| Q1 25 | $98.5M | $-166.5M | ||
| Q4 24 | $65.2M | $-79.3M | ||
| Q3 24 | $68.3M | $-67.0M | ||
| Q2 24 | $41.2M | $-77.0M | ||
| Q1 24 | $63.9M | $-190.7M |
自由现金流DOCSRARE
| Q4 25 | — | $-100.8M | ||
| Q3 25 | — | $-92.7M | ||
| Q2 25 | — | $-110.7M | ||
| Q1 25 | — | $-167.8M | ||
| Q4 24 | — | $-79.5M | ||
| Q3 24 | — | $-68.6M | ||
| Q2 24 | — | $-79.0M | ||
| Q1 24 | — | $-193.9M |
自由现金流率DOCSRARE
| Q4 25 | — | -48.6% | ||
| Q3 25 | — | -58.0% | ||
| Q2 25 | — | -66.5% | ||
| Q1 25 | — | -120.5% | ||
| Q4 24 | — | -48.3% | ||
| Q3 24 | — | -49.2% | ||
| Q2 24 | — | -53.7% | ||
| Q1 24 | — | -178.2% |
资本支出强度DOCSRARE
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | 0.0% | 1.0% | ||
| Q4 24 | 0.0% | 0.1% | ||
| Q3 24 | 0.0% | 1.2% | ||
| Q2 24 | 0.0% | 1.4% | ||
| Q1 24 | 0.0% | 3.0% |
现金转化率DOCSRARE
| Q4 25 | 0.99× | — | ||
| Q3 25 | 1.51× | — | ||
| Q2 25 | 1.16× | — | ||
| Q1 25 | 1.58× | — | ||
| Q4 24 | 0.87× | — | ||
| Q3 24 | 1.55× | — | ||
| Q2 24 | 1.00× | — | ||
| Q1 24 | 1.57× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DOCS
| Subscription | $175.4M | 95% |
| Service Other | $9.7M | 5% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
